Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. 

By Gwendolyn Wu • April 21, 2026

Trump executive order lifts psychedelics biotechs

Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more “investable space.”

By Jacob Bell • April 21, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

By BioPharma Dive's studioID • April 20, 2026

UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B

The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a hard-to-treat form of a common epilepsy.

By Jacob Bell • April 17, 2026

Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

By Ben Fidler • April 17, 2026

Kailera nets $625M in one of biotech’s biggest-ever IPOs

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to support a portfolio of medicines licensed from China’s Hengrui Pharma.

By Gwendolyn Wu • April 16, 2026

Replimune cuts staff; MeiraGTx reacquires eye gene therapy

Replimune is laying off 63 staffers days after the second FDA rejection of its melanoma drug. Elsewhere, Revolution raised $2 billion and a regulatory filing revealed details on negotiations between Biogen and Apellis.

By BioPharma Dive staff • April 16, 2026

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

By Delilah Alvarado • April 15, 2026

Terremoto raises $108M to pursue development of drugs targeting AKT

The California biotech has one therapy in Phase 1 testing and expects another to advance to the clinic later this year.

By Kristin Jensen • April 15, 2026

Travere wins long-awaited approval for kidney disease drug

The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity believed to be worth more than $1 billion annually. 

By Delilah Alvarado • April 14, 2026

Novo teams with OpenAI; Ideaya gets muted response to eye drug data

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into radiopharmaceuticals and a GSK cancer drug showed early promise.

By BioPharma Dive staff • April 14, 2026

Spyre drug for inflammatory bowel disease shows promise in early study

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” profile, the company said. 

By Delilah Alvarado • April 13, 2026

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy. 

By Gwendolyn Wu • April 13, 2026

Revolution pancreatic cancer drug nearly doubles survival in key trial

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor. 

By Jonathan Gardner • April 13, 2026

FDA again spurns Replimune melanoma drug

In a statement late Friday, CEO Sushil Patel disputed the FDA’s criticisms of the company and said Replimune had received “inconsistent communications.” It’ll be forced to cut jobs as well.

By Ben Fidler • Updated April 13, 2026

Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors

The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer. 

By Gwendolyn Wu • April 10, 2026

RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders

The newly published charter widens the required expertise to become an ACIP member and stresses vaccine safety. Elsewhere, Gilead licensed a Kymera drug and a new RNA-focused startup emerged. 

By Ben Fidler • April 10, 2026

Women have awaited a revolution in menopause. It hasn’t arrived.

Persistent barriers are still hindering drug development for a host of menopause symptoms.

By Kelly Bilodeau • April 10, 2026

Invivyd reveals plans to test an antibody drug against measles

The drug, which Invivyd sees as a potential treatment and “targeted alternative” for the vaccine-hesitant, comes as measles cases in the U.S. are reaching levels not seen in decades. 

By Delilah Alvarado • April 9, 2026

Chasing a tough-to-treat lung disease, Avalyn plans an IPO

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior versions of entrenched — but flawed — medicines for idiopathic pulmonary fibrosis.

By Gwendolyn Wu • April 9, 2026

Sidewinder secures $137M to advance ‘precision’ ADCs

Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.

By Delilah Alvarado • April 8, 2026

Activist investor revives campaign to overhaul Novavax board

Shah Capital, which has agitated for change at the vaccine maker for years, is calling on fellow shareholders to end what it calls “dogmatic leadership” that’s led to the “destruction” of Novavax’s equity value. 

By Kristin Jensen • April 8, 2026

Jeito Capital, prominent biotech investor, raises $1.2B for next fund

Jeito claimed the new bankroll, which will support 15 to 20 clinical-stage companies, is the largest ever for a “fully independent European fund dedicated to biopharma.”

By Gwendolyn Wu • April 8, 2026

Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure

Novo escalated a GLP-1 pricing war with the launch of its newest obesity medicine. Elsewhere, analysts came to Insmed’s defense and HHS changed the way panelists for a key vaccine committee are selected. 

By BioPharma Dive staff • April 8, 2026

Terns rebuffed a higher bid before selling to Merck

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

By Jonathan Gardner • April 7, 2026